Header

Welcome to RenValueSM

Sanofi is proud to help Commercially Insured and Cash patients cover the costs of Renvela® (sevelamer carbonate) tablets for up to 12 fills, through the RenValue program.

Who can use the RenValue card?

Patients with insurance

Commercially insured patients are responsible for the first $5, and can save up to $300 per fill.

Patients with no insurance

Cash patients can save up to $300 per fill.

Patients filling prescriptions that are covered by or submitted for reimbursement under Medicaid, Medicare, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program are not eligible for this offer. This program is not valid where prohibited by law, including in California and Massachusetts.

Coupon

To print the online RenValue coupon, click here.

RenVela Logo

To learn more about
Renvela, visit
www.renvela.com


Who cannot use the RenValue card?
Patients filling prescriptions that are covered by or submitted for reimbursement under Medicaid, Medicare, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program are not eligible for this offer. This program is not valid where prohibited by law, including in California and Massachusetts.

Indication

Renvela® (sevelamer carbonate) is used to control phosphorus levels in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.

Important Safety Information
  • Do not use Renvela if you have a history of bowel obstruction or if you are allergic to sevelamer carbonate, sevelamer hydrochloride or to any of the ingredients in Renvela.
  • Talk to your doctor if you have had difficulty swallowing or swallowing disorders; or if you have had digestive tract surgery or other digestive disorders, including severe constipation.
  • The most common side effects with sevelamer include vomiting, nausea, diarrhea, indigestion, abdominal pain, flatulence, and constipation.
  • Cases of itching, rash, fecal impaction and, less commonly, slow bowel activity, bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis and bowel perforation have been reported.
  • Uncommon cases of difficulty swallowing the Renvela tablet have been reported. Talk to your doctor if you have difficulty swallowing medicines in tablet form. Renvela for oral suspension may be considered by your doctor if you have a history of difficulty swallowing.
  • Your doctor should monitor your bicarbonate and chloride blood levels.
  • Reduced vitamins D, E, and K (clotting factors) and folic acid blood levels may be followed by your doctor.
  • Talk to your doctor when taking Renvela with other medications.
  • Promptly contact your doctor if you experience severe abdominal pain, new or worsening constipation, or other severe intestinal symptoms while on Renvela.
  • Take Renvela with meals and adhere to your prescribed diet.

Please see full Prescribing Information.

If you are a patient experiencing problems with a Sanofi US product while participating in the Renvalue Copay Program, please call Sanofi US at 1-866-257-4605.

© 2021 sanofi-aventis U.S. LLC. All rights reserved. MAT-US-2016128-v2.0-03/2021 Last Update: March 2021

Revela Logo
{"crx-wl-channel":"web","crx-wl-survey-description":"Agreement Certification","crx-wl-survey-name":"Renvela Patient Survey v1.0.0","brandName":"renvela","groupNumber":"EC41002034","resolveEnrollmentSearchFields":{"patient.firstName":{},"patient.lastName":{},"patient.dob":{},"patient.postalCode":{}},"client":"renvalue","brand":"renvela","brandPath":"renvela","view":"home"}